Parkinson-Klinik Ortenau, Kreuzbergstr. 12, Wolfach, Germany.
Expert Rev Neurother. 2023 Jan;23(1):9-13. doi: 10.1080/14737175.2023.2176222. Epub 2023 Feb 10.
In Parkinson's disease, oral medication often fails to achieve sufficient therapeutic success in an advanced stage. At this point, non-oral, device-aided therapies such as the apomorphine pump, the intrajejunal levodopa pump, and deep brain stimulation are discussed.
The purpose of this manuscript is to highlight a modern form of the well-known intestinal levodopa pump that allows for the continuation of the oral triple combination of levodopa, carbidopa and entacapone, a combination already used by many patients. This new form of pump has been available in both Austria and Germany since 2021, with entacapone being added to the combination to 'save' levodopa. The pump and cartridge are significantly smaller and lighter than the LCIG pump which should benefit therapeutic adherence.
Intrajejunal administration of levodopa is a useful treatment option for advanced Parkinson's disease. The higher acceptance of the smaller pump and the improved user-friendliness have already been reported in an observational study from Sweden. Clinical experience in Germany confirms this too and in addition to motor symptoms, even non-motor ones are influenced positively, and in this respect sleep and pain can be especially emphasized.
在帕金森病中，口服药物在晚期往往无法取得足够的治疗效果。此时，会讨论非口服、器械辅助的治疗方法，如阿扑吗啡泵、肠内左旋多巴泵和深部脑刺激。
本文的目的是强调一种著名的肠内左旋多巴泵的现代形式，该形式允许继续使用已被许多患者使用的口服左旋多巴、卡比多巴和恩他卡朋三联药物。这种新型的泵自 2021 年以来已在奥地利和德国上市，该组合中添加了恩他卡朋以“拯救”左旋多巴。与 LCIG 泵相比，泵和药筒的体积更小、重量更轻，这应该有助于提高治疗的依从性。
肠内给予左旋多巴是治疗晚期帕金森病的一种有效选择。瑞典的一项观察性研究已经报道了这种更小的泵更高的接受度和更好的用户友好性。德国的临床经验也证实了这一点，除了运动症状外，甚至非运动症状也受到积极影响，在这方面，睡眠和疼痛可以特别强调。
